Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139797 · ClinicalTrials.gov registry record
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
A clinical trial of Cardiac Amyloidosis, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT05139797 is a study of Cardiac Amyloidosis that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 300 participants, below the 917-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05139797, a study of Cardiac Amyloidosis, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.
Conditions Studied
Interventions
- OTHER EchoNet-LVH screening for cardiac amyloidosis
Study Locations (1)
California
- Cedars-Sinai Medical Centre (Los Angeles) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2027-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05139797
The ClinicalTrials.gov registry entry for NCT05139797 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 917-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (67% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which EchoNet-LVH screening for cardiac amyloidosis is the first listed.
NCT05139797 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05139797 about?
NCT05139797 is a clinical study titled "Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)". Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advances in machine learnin...
What is the current status of trial NCT05139797?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-11-18. Estimated completion is 2027-06-01.
What conditions does trial NCT05139797 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis.
What interventions are being tested in trial NCT05139797?
The interventions under investigation include: EchoNet-LVH screening for cardiac amyloidosis (OTHER).
Who is sponsoring clinical trial NCT05139797?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05139797 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
RECRUITING · NA
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
US Benchmarking Clinical Study
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
-
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.